Dentsply Sirona Amends Credit Agreements to Loosen Leverage Covenants Through 2026
XRAY is trading near its 52-week low of $8.38 (5.4% above the low).
Summary
Dentsply Sirona amended its credit agreements to loosen leverage covenants through year-end 2026, adding an EBITDA addback and new pricing, in exchange for restrictions on liens, subsidiary debt, and restricted payments.
Key Events · Financing and Capital Events · XRAY
-
Leverage Covenants Loosened Through 2026
Maximum permitted Total Leverage Ratio and Senior Leverage Ratio increased for fiscal quarters ending September 30, 2026 and December 31, 2026, indicating the company was at risk of breaching its debt covenants.
-
EBITDA Addback of Up to $100M
Amendments permit an additional addback to EBITDA for certain cash charges or expenses incurred during fiscal quarters ending September 30, 2026 and December 31, 2026, in an amount not to exceed $100,000,000 in the aggregate.
-
New Pricing and Incremental Interest
Third Amendment to Credit Agreement adds a new pricing level for the applicable margin and facility fee, and Note Purchase Agreement Amendments increase incremental interest payable on notes if total leverage ratio equals or exceeds specified thresholds.
-
Restrictions During Specified Period
Until delivery of compliance certificate for fiscal year ending December 31, 2026, the company generally cannot incur new liens or new subsidiary debt, and restricted payments are limited with certain carveouts.
Analysis · XRAY · Industrial Applications And Services
Lender consent was obtained to amend the revolving credit facility and three note purchase agreements, raising the maximum permitted Total Leverage Ratio and Senior Leverage Ratio for the fiscal quarters ending September 30, 2026 and December 31, 2026. The amendments also introduce an EBITDA addback of up to $100 million for certain cash charges, add a new pricing level for the revolver, and increase incremental interest on notes if leverage thresholds are exceeded. In exchange, the company agreed to restrictions on new liens, subsidiary debt, and restricted payments during the Specified Period, plus additional quarterly reporting. This signals the company was at risk of breaching its debt covenants and needed breathing room, but the lenders extracted concessions in return.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRAY was trading at $8.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $8.38 to $14.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.